Basilea Pharmaceutica Ag
Rank #845 of 1,000 by FY2025 federal contract value
FY2025 contract value
$63,700,481
Oct 1, 2024 – Sep 30, 2025
FY2024 contract value
$27,539,470
FY2023 contract value
$0
Top agency (FY2025)
Department of Health and Human Services
$63,700,481
Company profile
- Legal name (as listed)
- BASILEA PHARMACEUTICA AG
- UEI
- Z9A6DMV55YP3
- DUNS
- 481286388
- Headquarters
- Not listed
- Business types
- Not listed
Contract value trend, FY2023 – FY2025
| Fiscal year | Contract value | Change vs prior year |
|---|---|---|
| FY2023 | $0 | — |
| FY2024 | $27,539,470 | — |
| FY2025 | $63,700,481 | +131.3% |
FY2025 breakdowns
Top 10 in each category by FY2025 contract value.
Top awarding agencies
| Department of Health and Human ServicesHHS | $63,700,481 |
Top places of performance (states)
| PennsylvaniaPA | $0 |
Top industries (NAICS)
| Research and Development in Biotechnology (except Nanobiotechnology)541714 | $63,819,710 |
| Research and Development in Biotechnology541711 | -$119,229 |
Top product & service codes (PSC)
| HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCHAN42 | $63,819,710 |
| HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENTAN13 | -$119,229 |
Contract awards
Up to 20 awards with activity in FY2025, newest start date first. Amounts are individual award obligations, not company totals.
CONT_AWD_75A50124C00033_7505_-NONE-_-NONE-
$122,501,232
Awarding agency: Department of Health and Human Services
Description: THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA
Start date: Sep 30, 2024
NAICS: —
PSC: —
Place: —
CONT_AWD_75A50123C00050_7505_-NONE-_-NONE-
$45,192,122
Awarding agency: Department of Health and Human Services
Description: VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS.
Start date: Sep 15, 2023
NAICS: —
PSC: —
Place: PA
CONT_AWD_HHSO100201600002C_7505_-NONE-_-NONE-
$108,445,187
Awarding agency: Department of Health and Human Services
Description: IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE
Start date: Apr 19, 2016
NAICS: —
PSC: —
Place: —
CONT_AWD_HHSO100201300010C_7505_-NONE-_-NONE-
$13,096,576
Awarding agency: Department of Health and Human Services
Description: IGF::OT::IGF FOR OTHER FUNCTIONS THIS CONTRACT IS FOR THE CLINICAL DEVELOPMENT OF BAL30072, A NOVEL MONOSULFACTAM FOR THE TREATMENT OF INFECTIONS CAUSED BY MULTI-DRUG RESISTANT GRAM-NEGATIVE BACTERIAL PATHOGENS.
Start date: Jun 19, 2013
NAICS: —
PSC: —
Place: —
NAICS and PSC are not reported for these awards in USAspending.
Source: USAspending.gov. Company totals are sums of all contract obligations across the company's USAspending recipient records for each fiscal year. This page is not affiliated with or endorsed by the U.S. government.